[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354123-105":59,"doc-detail-354123-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","age-related-genomic-characterization-and-therapeutic-targets-in-chinese-breast-cancer-insights-from-prospective-targeted-sequencing-and-clinical-data-analysis","Age-related genomic characterization and therapeutic targets in Chinese breast cancer: insights from prospective targeted sequencing and clinical data analysis","","In China, breast cancer affects younger patients more often and is linked to higher recurrence and mortality, while aging trends are shifting incidence toward older ages. Large next-generation sequencing cohorts remain limited for defining genomic profiles and therapeutic targets in these groups. This study uses prospective targeted sequencing of tumor and blood samples plus detailed clinical data, comparing patients \u003C40 and ≥40 to describe somatic and germline mutation landscapes and evaluate age-specific treatment opportunities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/age-related-genomic-characterization-and-therapeutic-targets-in-chinese-breast-cancer-insights-from-prospective-targeted-sequencing-and-clinical-data-analysis/354123/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/age-related-genomic-characterization-and-therapeutic-targets-in-chinese-breast-cancer-insights-from-prospective-targeted-sequencing-and-clinical-data-analysis/354123.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does the study focus on age-related differences in Chinese breast cancer?","Question",{"text":112,"@type":113},"It addresses the observation that breast cancer occurs at a much younger age in China and is associated with higher recurrence and mortality, while incidence patterns are also shifting toward older ages. The work aims to clarify genomic differences and identify therapeutic targets for these age groups.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients grouped in the analysis?",{"text":117,"@type":113},"Patients were categorized into two groups based on age: \u003C40 years (n = 637) and ≥40 years (n = 3442). The study then compared somatic and germline mutations across both groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What key therapeutic implications were found for elderly versus young patients?",{"text":121,"@type":113},"Elderly patients showed higher prevalence of PIK3CA, FOXA1, and TBX3 mutations, supporting potential benefit from PI3K-AKT-mTOR pathway inhibitors. Young women showed higher rates of TP53 and ERBB2 co-mutations, with worse prognosis, but greater likelihood of benefiting from immune checkpoint inhibitor combination with tyrosine kinase inhibitor therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354123,1792113271,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Sui et al. BMC Medicine (2026) 24:293 [https://doi.org/10.1186/s12916-026-04655-9](https://doi.org/10.1186/s12916-026-04655-9)  \nBMC Medicine  \n RESEARCH Open Access  \nAge-related genomic characterization and therapeutic targets in Chinese breast cancer: insights from prospective targeted sequencing and clinical data analysis  \nXin-Yi Sui 1,2†, Xiao-Qing Song3†, Xi-Yu Liu 1,2, Zhi-Ming Shao1,2, Xin Hu 1,4*, Chao Chen1,2* and Lei Fan 1,2*  \nAbstract  \nBackground In China, breast cancer occurs at a much younger age and has a higher recurrence and mortality rate. However, with changes in lifestyle, there has been a trend towards an older age of breast cancer incidence in Chinese women. There is a paucity of large-scale next-generation sequencing cohorts for the analysis of genomic characterization in these populations and the identification of potential therapeutic targets.  \nMethods To address this gap, we performed prospective targeted sequencing of tumor and blood samples from Chinese patients and collected detailed clinical information. We then categorized patients into two groups based on age (\u003C 40 years, n = 637; ≥ 40 years, n = 3442) and proceeded to provide comprehensive descriptions of somatic and germline mutations in both groups.  \nResults The somatic mutation analysis revealed that PIK3CA, FOXA1, and TBX3 mutations were more prevalent in elderly patients. By leveraging the aforementioned mutational characteristics, we employed our institution’s FUTURE-SUPER clinical trial, an umbrella study targeting metastatic breast cancer, to confirm the potential benefits of PI3K-AKT-mTOR pathway inhibitors among elderly patients with breast cancer. Furthermore, TP53 and ERBB2 were more likely to be co-mutated in young women. Patients with TP53 and ERBB2 co-mutation tend to have a poorer prognosis, but through investigation of the SPARK cohort, patients carrying the TP53 and ERBB2 co-mutation are more likely to benefit from immune checkpoint inhibitor combination with tyrosine kinase inhibitor therapy. In our study, we observed a higher frequency of mutations in the DNA homology-dependent recombination pathway in young patients with breast cancer, which was associated with an elevated Ki67 index. Additionally, we confirmed a significant prevalence of germline breast cancer susceptibility gene 1 (gBRCA1) mutations in young patients, whereas germline checkpoint kinase 2 (gCHEK2) mutations are more common in elderly patients.  \n†Xin-Yi Sui and Xiao-Qing Song contributed equally to this work.  \n*Correspondence:  \nXin Hu [xinhu@fudan.edu.cn](xinhu@fudan.edu.cn)[ ](xinhu@fudan.edu.cn)Chao Chen [chao_chen@fudan.edu.cn](chao_chen@fudan.edu.cn)[ ](chao_chen@fudan.edu.cn)Lei Fan  \n[teddyfl@163.com](teddyfl@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nSui et al. BMC Medi","cbCaikbB2Ka6dmdz","https://ap.wps.com/l/cbCaikbB2Ka6dmdz","pdf",3454387,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"Why does the study focus on age-related differences in Chinese breast cancer?\",\"answer\":\"It addresses the observation that breast cancer occurs at a much younger age in China and is associated with higher recurrence and mortality, while incidence patterns are also shifting toward older ages. The work aims to clarify genomic differences and identify therapeutic targets for these age groups.\"},{\"question\":\"How were patients grouped in the analysis?\",\"answer\":\"Patients were categorized into two groups based on age: \\u003c40 years (n = 637) and ≥40 years (n = 3442). The study then compared somatic and germline mutations across both groups.\"},{\"question\":\"What key therapeutic implications were found for elderly versus young patients?\",\"answer\":\"Elderly patients showed higher prevalence of PIK3CA, FOXA1, and TBX3 mutations, supporting potential benefit from PI3K-AKT-mTOR pathway inhibitors. Young women showed higher rates of TP53 and ERBB2 co-mutations, with worse prognosis, but greater likelihood of benefiting from immune checkpoint inhibitor combination with tyrosine kinase inhibitor therapy.\"}]","Age-related genomic characterization and therapeutic targets in Chinese breast cancer: insights from prospective targeted sequencing and clinical data analysis | PDF",1790109119,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f570f3a48bd28d29cac95203704705e7.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/700ffa395d491c7e203f64a9d6783486.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b30c416a510757dda5f1478baa556511.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9d6113e04603767b4b02b425ffa80c6.webp",980,1301]